Down 99%, biotech firm 180 Life Sciences pivots to crypto with ETH bet

The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.

Related Posts

Leave a Reply

Recent Articles

$19B crypto market crash: Was it leverage, China tariffs or both?
October 14, 2025
BitMine adds over 200K ETH in ‘aggressive’ post-crash weekend buying
October 14, 2025
A state-backed crypto fund just made its first buy — and it wasn’t Bitcoin
October 14, 2025

Text Widget

Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.

Post Category